TDO2 and non-small cell lung carcinoma: Together, our data strongly support the presence of a compensatory mechanism wherein cisplatin-resistant NSCLC tumors can employ IDO1 and/or TDO2 activation to overcome single enzyme pharmacological blockade as therapy.